New combo aims to shrink radiation damage in head and neck cancer
NCT ID NCT06706401
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two ideas at once: adding a drug called ATRA (Vesanoid) to standard treatment, and using a smaller radiation area that targets the tumor more precisely. It includes 460 adults with certain types of head and neck cancer that haven't spread across the midline. The goal is to see if these approaches help people live longer without the cancer coming back, while possibly reducing side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- all-trans retinoic acid (ATRA, also known as Vesanoid) and radiotherapy
- What this could lead to
- If successful, this could lead to a new standard treatment that reduces side effects and improves cancer control for certain head and neck cancers.
- What could go wrong
- This is a phase 3 trial, but results are not guaranteed. ATRA may cause side effects like skin dryness or liver issues, and reducing radiotherapy volume might not control the cancer as well.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AP-HP - Hôpital Tenon
RECRUITINGParis, 75020, France
-
Centre Antoine Lacassagne
RECRUITINGNice, 06189, France
-
Centre Léon Bérard
RECRUITINGLyon, France, 69008, France
-
Centre Oscar Lambret
RECRUITINGLille, 59000, France
-
Institut Godinot
RECRUITINGReims, France
-
Institut Gustave Roussy
RECRUITINGVillejuif, France, 94805, France
-
Institut de Cancérologie de Lorraine
RECRUITINGVandœuvre-lès-Nancy, France, 54519, France
-
Institut de Cancérologie de l'Ouest - Paul Papin
RECRUITINGAngers, 49055, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can less radiation be safer for throat cancer?
- Could a PET scan spare throat cancer patients from High-Dose radiation?
- Can a simple swab predict who needs less radiation?
- Could less be more? trial tests reduced radiation and chemo after surgery for HPV-Linked throat cancer
- New drug combo aims to shrink oral cancers before surgery
- Acupuncture timing may be key to preventing dry mouth in head and neck cancer patients